Paige.AI, a New York based startup focused on improving clinical diagnosis and treatment in pathology and oncology through the use of artificial intelligence (AI), said that Dr. Leo Grady has joined the company as CEO and a member of its Board of Directors.
Launched in 2018 based on technology developed by its Co-Founder and Chief Scientific Officer, Dr. Thomas Fuchs, and a license agreement with Memorial Sloan Kettering Cancer Center (MSK), Paige.AI is initially focused on developing a full suite of modules and products for diagnostic pathologists.
Grady is a seasoned healthcare technology leader with more than 15 years of experience in prototyping, developing, and bringing to market some of the industry’s most advanced machine learning, computer vision, and medical imaging technologies and products.
Prior to joining Paige.AI, he was Senior Vice President of Engineering for HeartFlow, a medical technology company recently valued at more than $1.5 billion, that leverages deep learning to transform the way cardiac disease is diagnosed and treated.
He is internationally recognized for his scientific work on advanced technology for medical imaging and machine learning, has published two books and over 100 peer-reviewed journal and conference papers, and has over 300 issued or pending patents worldwide.
In 2014, Grady was inducted as a Fellow in the American Institute for Medical and Biological Engineering. In 2012, he was the recipient of the Edison Patent Award in medical imaging. He received a B.Sc. degree in Electrical Engineering at the University of Vermont and a Ph.D. in Cognitive and Neural Systems from Boston University.